Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths
NCT01788774 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2023-10-23
Summary
This clinical trial is designed to evaluate different dosages of risperidone ISM, a new long-acting injectable form.
Conditions
- Schizophrenia
- Schizoaffective Disorder
Interventions
- DRUG
-
Risperidone ISM 50 mg
- DRUG
-
Risperidone ISM 75 mg
- DRUG
-
Risperidone ISM 100 mg
Sponsors & Collaborators
-
Rovi Pharmaceuticals Laboratories
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-04-30
- Primary Completion
- 2014-02-28
- Completion
- 2014-02-28
Countries
- Croatia
- Russia
- South Africa
- Spain
Study Locations
More Related Trials
-
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
NCT00495118 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative Bioavailability of Risperidone
NCT03527186 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients
NCT00653406 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
NCT00558298 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
NCT01855074 ·Status: COMPLETED ·Phase: PHASE4
-
Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy
NCT01677377 ·Status: COMPLETED ·Phase: PHASE2
-
Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse
NCT05480046 ·Status: COMPLETED
-
A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia
NCT00253136 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
NCT00240708 ·Status: COMPLETED ·Phase: PHASE3
-
Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia
NCT00821600 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.
NCT00034775 ·Status: COMPLETED ·Phase: PHASE3
-
A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia
NCT00236587 ·Status: COMPLETED ·Phase: PHASE3
-
A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia
NCT00249223 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
NCT00992407 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone
NCT00563017 ·Status: UNKNOWN ·Phase: NA
-
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
NCT00210691 ·Status: COMPLETED ·Phase: PHASE3
-
Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder
NCT01888107 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment
NCT00526877 ·Status: COMPLETED ·Phase: PHASE4
-
A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.
NCT00843687 ·Status: COMPLETED ·Phase: PHASE3
-
Study of a Novel Antipsychotic ITI-007 in Schizophrenia
NCT01499563 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
NCT02469155 ·Status: COMPLETED ·Phase: PHASE3
-
Risperidone and Suicidality in Major Depressive Disorder
NCT00167154 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Seroquel in First Episode Schizophrenia
NCT00254241 ·Status: COMPLETED ·Phase: PHASE4
-
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
NCT00539071 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
NCT00269919 ·Status: COMPLETED ·Phase: PHASE4